{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:16:33Z","timestamp":1784672193583,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072141, 82272240, 82202376"],"award-info":[{"award-number":["82072141, 82272240, 82202376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072141, 82272240, 82202376"],"award-info":[{"award-number":["82072141, 82272240, 82202376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072141, 82272240, 82202376"],"award-info":[{"award-number":["82072141, 82272240, 82202376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH225"],"award-info":[{"award-number":["ZR2022QH225"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Foundation of Shandong University","award":["2020SDUCRCC014"],"award-info":[{"award-number":["2020SDUCRCC014"]}]},{"name":"State Key Program of the National Natural Science Foundation of China","award":["82030059"],"award-info":[{"award-number":["82030059"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-024-02477-8","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T12:01:54Z","timestamp":1729944114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling"],"prefix":"10.1186","volume":"23","author":[{"given":"Han","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"issue":"3","key":"2477_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1161\/CIRCULATIONAHA.121.058655","volume":"147","author":"H Tani","year":"2023","unstructured":"Tani H, Sadahiro T, Yamada Y, Isomi M, Yamakawa H, Fujita R, Abe Y, Akiyama T, Nakano K, Kuze Y, et al. Direct reprogramming improves cardiac function and reverses fibrosis in chronic myocardial infarction. Circulation. 2023;147(3):223\u201338.","journal-title":"Circulation"},{"issue":"18","key":"2477_CR2","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"key":"2477_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.870924","volume":"9","author":"R Chai","year":"2022","unstructured":"Chai R, Xue W, Shi S, Zhou Y, Du Y, Li Y, Song Q, Wu H, Hu Y. Cardiac remodeling in heart failure: role of pyroptosis and its therapeutic implications. Front Cardiovasc Med. 2022;9:870924.","journal-title":"Front Cardiovasc Med"},{"issue":"18","key":"2477_CR4","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.jacc.2011.06.058","volume":"58","author":"A Gonzalez","year":"2011","unstructured":"Gonzalez A, Ravassa S, Beaumont J, Lopez B, Diez J. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol. 2011;58(18):1833\u201343.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2477_CR5","first-page":"1","volume":"4","author":"J Xing","year":"2024","unstructured":"Xing J. Venoarterial extracorporeal membrane oxygenation in acute myocardial infarction. Emerg Crit Care Med. 2024;4(1):1\u20133.","journal-title":"Emerg Crit Care Med"},{"issue":"36","key":"2477_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"key":"2477_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"V Vallon","year":"2015","unstructured":"Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255\u201370.","journal-title":"Annu Rev Med"},{"issue":"5","key":"2477_CR8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/joim.13620","volume":"293","author":"N Girerd","year":"2023","unstructured":"Girerd N, Zannad F. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: finding the right patients to treat. J Intern Med. 2023;293(5):550\u20138.","journal-title":"J Intern Med"},{"key":"2477_CR9","doi-asserted-by":"crossref","unstructured":"Li X, Lu Q, Qiu Y, do Carmo JM, Wang Z, da Silva AA, Mouton A, Omoto ACM, Hall ME, Li J, et al. Direct cardiac actions of the sodium glucose co\u2010transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure\u2010overload heart failure. J Am Heart Assoc. 2021;10(6).","DOI":"10.1161\/JAHA.120.018298"},{"key":"2477_CR10","doi-asserted-by":"crossref","unstructured":"Ni L, Yuan C, Chen G, Zhang C, Wu X: SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19(1).","DOI":"10.1186\/s12933-020-01071-y"},{"issue":"15","key":"2477_CR11","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2477_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jacc.2011.01.059","volume":"58","author":"MT Maeder","year":"2011","unstructured":"Maeder MT, Khammy O, dos Remedios C, Kaye DM. Myocardial and systemic iron depletion in heart failure. J Am Coll Cardiol. 2011;58(5):474\u201380.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2477_CR13","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s44161-023-00352-5","volume":"2","author":"CE Angermann","year":"2023","unstructured":"Angermann CE, Santos-Gallego CG, Requena-Ibanez JA, Sehner S, Zeller T, Gerhardt LMS, Maack C, Sanz J, Frantz S, Fuster V, et al. Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure. Nat Cardiovasc Res. 2023;2(11):1032\u201343.","journal-title":"Nat Cardiovasc Res"},{"key":"2477_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110072","volume":"118","author":"Y Chen","year":"2023","unstructured":"Chen Y, Peng D. New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling. Int Immunopharmacol. 2023;118: 110072.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"2477_CR15","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1161\/ATVBAHA.119.312946","volume":"39","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Wang B, Zhang J, He D, Zhang Q, Pan C, Yuan Q, Shi Y, Tang H, Xu F, et al. ALDH2 (Aldehyde Dehydrogenase 2) protects against hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2019;39(11):2303\u201319.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"2477_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41569-023-00839-5","volume":"20","author":"J Zhang","year":"2023","unstructured":"Zhang J, Guo Y, Zhao X, Pang J, Pan C, Wang J, Wei S, Yu X, Zhang C, Chen Y, et al. The role of aldehyde dehydrogenase 2 in cardiovascular disease. Nat Rev Cardiol. 2023;20(7):495\u2013509.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"2477_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41419-020-02805-2","volume":"11","author":"W Li","year":"2020","unstructured":"Li W, Yin L, Sun X, Wu J, Dong Z, Hu K, Sun A, Ge J. Alpha-lipoic acid protects against pressure overload-induced heart failure via ALDH2-dependent Nrf1-FUNDC1 signaling. Cell Death Dis. 2020;11(7):599.","journal-title":"Cell Death Dis"},{"key":"2477_CR18","doi-asserted-by":"crossref","unstructured":"Guo H, Yu X, Liu Y, Paik DT, Justesen JM, Chandy M, Jahng JWS, Zhang T, Wu W, Rwere F et al: SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant. Sci Transl Med. 2023;15(680):eabp9952.","DOI":"10.1126\/scitranslmed.abp9952"},{"issue":"1","key":"2477_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/EC9.0000000000000097","volume":"4","author":"H Rui","year":"2024","unstructured":"Rui H, Yu H, Zou D, Chi K, Xu P, Song X, Liu L, Wu X, Wang J, Xue L. Vaspin alleviates pathological cardiac hypertrophy by regulating autophagy-dependent myocardial senescence. Emerg Crit Care Med. 2024;4(1):4\u201315.","journal-title":"Emerg Crit Care Med"},{"key":"2477_CR20","doi-asserted-by":"crossref","unstructured":"Lin K, Yang N, Luo W, Qian J-f, Zhu W-w, Ye S-j, Yuan C-x, Xu D-y, Liang G, Huang W-j, et al. Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling. Acta Pharmacol Sin. 2022;43(10):2624\u201335.","DOI":"10.1038\/s41401-022-00885-8"},{"key":"2477_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102979","volume":"69","author":"X Li","year":"2024","unstructured":"Li X, Wang M, Kalina JO, Preckel B, Hollmann MW, Albrecht M, Zuurbier CJ, Weber NC. Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE\/PKC\/NOX axis. Redox Biol. 2024;69: 102979.","journal-title":"Redox Biol"},{"key":"2477_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2018.04.082","volume":"268","author":"S Costantino","year":"2018","unstructured":"Costantino S, Paneni F, Mitchell K, Mohammed SA, Hussain S, Gkolfos C, Berrino L, Volpe M, Schwarzwald C, Luscher TF, et al. Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66(Shc). Int J Cardiol. 2018;268:179\u201386.","journal-title":"Int J Cardiol"},{"issue":"9970","key":"2477_CR23","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S0140-6736(14)61889-4","volume":"385","author":"E Braunwald","year":"2015","unstructured":"Braunwald E. The war against heart failure: the Lancet lecture. The Lancet. 2015;385(9970):812\u201324.","journal-title":"The Lancet"},{"issue":"1","key":"2477_CR24","first-page":"312","volume":"13","author":"D Catalucci","year":"2008","unstructured":"Catalucci D, Latronico MVG, Ellingsen O, Condorelli G. Physiological myocardial hypertrophy: How and why? FBL. 2008;13(1):312\u201324.","journal-title":"FBL"},{"issue":"7181","key":"2477_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/nature06798","volume":"451","author":"JO Mudd","year":"2008","unstructured":"Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature. 2008;451(7181):919\u201328.","journal-title":"Nature"},{"issue":"12","key":"2477_CR26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"6","key":"2477_CR27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2337\/db07-1472","volume":"57","author":"S Han","year":"2008","unstructured":"Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723\u20139.","journal-title":"Diabetes"},{"issue":"1","key":"2477_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021;83(1):503\u201328.","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"2477_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","volume":"147","author":"S Chen","year":"2023","unstructured":"Chen S, Wang Q, Christodoulou A, Mylonas N, Bakker D, Nederlof R, Hollmann MW, Weber NC, Coronel R, Wakker V, et al. Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2. Circulation. 2023;147(3):276\u20139.","journal-title":"Circulation"},{"key":"2477_CR30","doi-asserted-by":"crossref","unstructured":"van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol. 2022;18(5):294\u2013306.","DOI":"10.1038\/s41581-022-00535-6"},{"key":"2477_CR31","doi-asserted-by":"crossref","unstructured":"Gao M, Bhatia K, Kapoor A, Badimon J, Pinney SP, Mancini DM, Santos-Gallego CG, Lala A: SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure. JAMA Network Open. 2024;7(4).","DOI":"10.1001\/jamanetworkopen.2024.5135"},{"key":"2477_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115125","volume":"165","author":"J Yang","year":"2023","unstructured":"Yang J, Li L, Zheng X, Lu Z, Zhou H. Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1\/HIF-1\u03b1 signaling pathway. Biomed Pharmacother. 2023;165: 115125.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2477_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","volume":"19","author":"M Arow","year":"2020","unstructured":"Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG, Freimark D, Kornowski R, Aravot D, Hochhauser E, et al. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol. 2020;19(1):7.","journal-title":"Cardiovasc Diabetol"},{"key":"2477_CR34","doi-asserted-by":"crossref","unstructured":"Yang K, Cui S, Wang J, Xu T, Du H, Yue H, Ye H, Guo J, Zhang J, Li P, et al. Early Progression of abdominal aortic aneurysm is decelerated by improved endothelial barrier function via ALDH2\u2010LIN28B\u2010ELK3 signaling. Adv Sci. 2023;10(32).","DOI":"10.1002\/advs.202302231"},{"issue":"1","key":"2477_CR35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1172\/JCI122064","volume":"129","author":"S Zhong","year":"2019","unstructured":"Zhong S, Li L, Zhang YL, Zhang L, Lu J, Guo S, Liang N, Ge J, Zhu M, Tao Y, et al. Acetaldehyde dehydrogenase 2 interactions with LDLR and AMPK regulate foam cell formation. J Clin Invest. 2019;129(1):252\u201367.","journal-title":"J Clin Invest"},{"key":"2477_CR36","doi-asserted-by":"crossref","unstructured":"Li W, Yin L, Sun X, Wu J, Dong Z, Hu K, Sun A, Ge J. Alpha-lipoic acid protects against pressure overload-induced heart failure via ALDH2-dependent Nrf1-FUNDC1 signaling. Cell Death Dis. 2020;11(7).","DOI":"10.1038\/s41419-020-02805-2"},{"key":"2477_CR37","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zou R, Abudureyimu M, Liu Q, Ma J, Xu H, Yu W, Yang J, Jia J, Qian S et al: Mitochondrial aldehyde dehydrogenase rescues against diabetic cardiomyopathy through GSK3\u03b2-mediated preservation of mitochondrial integrity and Parkin-mediated mitophagy. J Mol Cell Biol. 2023;15(9).","DOI":"10.1093\/jmcb\/mjad056"},{"key":"2477_CR38","doi-asserted-by":"crossref","unstructured":"Palmiero G, Cesaro A, Vetrano E, Pafundi PC, Galiero R, Caturano A, Moscarella E, Gragnano F, Salvatore T, Rinaldi L, et al. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci. 2021;22(11).","DOI":"10.3390\/ijms22115863"},{"key":"2477_CR39","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","volume":"9","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW, Coronel R, Weber NC, Zuurbier CJ. Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol. 2018;9:1575.","journal-title":"Front Physiol"},{"key":"2477_CR40","doi-asserted-by":"crossref","unstructured":"Berger JH, Matsuura TR, Bowman CE, Taing R, Patel J, Lai L, Leone TC, Reagan JD, Haldar SM, Arany Z, et al. SGLT2 inhibitors act independently of SGLT2 to confer benefit for HFrEF in mice. Circ Res. 2024.","DOI":"10.1161\/CIRCRESAHA.124.324823"},{"key":"2477_CR41","doi-asserted-by":"crossref","unstructured":"Xia H, Zahra A, Jia M, Wang Q, Wang Y, Campbell SL, Wu J. Na(+)\/H(+) Exchanger 1, a potential therapeutic drug target for cardiac hypertrophy and heart failure. Pharmaceuticals. 2022;15(7).","DOI":"10.3390\/ph15070875"},{"issue":"1","key":"2477_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.hipert.2019.09.002","volume":"37","author":"AM Yeves","year":"2020","unstructured":"Yeves AM, Ennis IL. Na(+)\/H(+) exchanger and cardiac hypertrophy. Hipertens Riesgo Vasc. 2020;37(1):22\u201332.","journal-title":"Hipertens Riesgo Vasc"},{"key":"2477_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116477","volume":"174","author":"S Chen","year":"2024","unstructured":"Chen S, Overberg K, Ghouse Z, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK\/NHE-1 inhibition. Biomed Pharmacother. 2024;174: 116477.","journal-title":"Biomed Pharmacother"},{"key":"2477_CR44","doi-asserted-by":"crossref","unstructured":"Chen S, Wang Q, Bakker D, Hu X, Zhang L, van der Made I, Tebbens AM, Kovacshazi C, Giricz Z, Brenner GB, et al: Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. Basic Res Cardiol. 2024.","DOI":"10.1007\/s00395-024-01067-9"},{"issue":"7","key":"2477_CR45","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00204-022-03298-y","volume":"96","author":"W-T Chang","year":"2022","unstructured":"Chang W-T, Shih J-Y, Lin Y-W, Chen Z-C, Kan W-C, Lin T-H, Hong C-S. Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3. Arch Toxicol. 2022;96(7):2021\u201332.","journal-title":"Arch Toxicol"},{"key":"2477_CR46","doi-asserted-by":"crossref","unstructured":"Santos-Gallego CG, Requena-Ib\u00e1\u00f1ez JA, Picatoste B, Fardman B, Ishikawa K, Mazurek R, Pieper M, Sartori S, Rodriguez-Capit\u00e1n J, Fuster V, et al. Cardioprotective effect of empagliflozin and circulating ketone bodies during acute myocardial infarction. Circ Cardiovasc Imaging. 2023;16(4).","DOI":"10.1161\/CIRCIMAGING.123.015298"},{"key":"2477_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102674","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Fan X, Wang Q, Zhen J, Li X, Zhou P, Lang Y, Sheng Q, Zhang T, Huang T, et al. ROS promote hyper-methylation of NDRG2 promoters in a DNMTS-dependent manner: contributes to the progression of renal fibrosis. Redox Biol. 2023;62: 102674.","journal-title":"Redox Biol"},{"issue":"12","key":"2477_CR48","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1593\/neo.07712","volume":"9","author":"AC Campos","year":"2007","unstructured":"Campos AC, Molognoni F, Melo FH, Galdieri LC, Carneiro CR, D\u2019Almeida V, Correa M, Jasiulionis MG. Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. Neoplasia. 2007;9(12):1111\u201321.","journal-title":"Neoplasia"},{"key":"2477_CR49","doi-asserted-by":"crossref","unstructured":"Yang M, Wang A, Li C, Sun J, Yi G, Cheng H, Liu X, Wang Z, Zhou Y, Yao G, et al. Methylation-induced silencing of ALDH2 facilitates lung adenocarcinoma bone metastasis by activating the MAPK pathway. Front Oncol. 2020;10.","DOI":"10.3389\/fonc.2020.01141"},{"key":"2477_CR50","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.csbj.2023.02.045","volume":"21","author":"T-O Tran","year":"2023","unstructured":"Tran T-O, Vo TH, Lam LHT, Le NQK. ALDH2 as a potential stem cell-related biomarker in lung adenocarcinoma: Comprehensive multi-omics analysis. Comput Struct Biotechnol J. 2023;21:1921\u20139.","journal-title":"Comput Struct Biotechnol J"},{"key":"2477_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijcard.2017.09.188","volume":"250","author":"S Costantino","year":"2018","unstructured":"Costantino S, Camici GG, Mohammed SA, Volpe M, L\u00fcscher TF, Paneni F. Epigenetics and cardiovascular regenerative medicine in the elderly. Int J Cardiol. 2018;250:207\u201314.","journal-title":"Int J Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02477-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02477-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02477-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T12:02:17Z","timestamp":1729944137000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02477-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2477"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02477-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"27 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study adhered to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Qilu Hospital of Shandong University. All animal studies were approved by the Institutional Animal Care and Use Committee of Qilu Hospital of Shandong University (DWLL-2023-138).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"380"}}